Overview

The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy

Status:
Completed

Trial end date:
2017-09-30

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer who were treated with intensive chemotherapy for prevention of neutrophil reduction.

Phase:

Phase 4

Details

Lead Sponsor:

Peking University

Treatments:

Lenograstim